Latest action: Referred to the House Committee on Energy and Commerce.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Protects safety net providers from high drug prices.
The problem
Safety net providers serving low-income patients may struggle with rising pharmaceutical costs, potentially limiting access to medicines for vulnerable populations.
The proposal
The bill likely establishes protections or pricing limits on drugs purchased by safety net healthcare providers, such as community health centers and safety-net hospitals.
The impact
Safety net providers, low-income patients, pharmaceutical companies, and the healthcare system are affected through changed drug pricing mechanisms and potential medication access shifts.
Safety net providers could reduce drug expenses, freeing resources for other patient care needs. This helps organizations stretch limited budgets. Patients may access medications more affordably.
Low-income patients relying on safety net clinics could gain better medicine access. Fewer people skip medications due to cost. Public health outcomes may improve.
Community health centers and hospitals serving the poor receive financial relief. Organizations can maintain services despite budget pressures. More clinics stay open in underserved areas.
Price controls can discourage pharmaceutical companies from developing new medicines. Companies may earn less profit from research investments. Future treatment options could be limited.
Drug makers might raise prices elsewhere to offset safety net discounts. Insurance premiums or patient costs in other sectors could rise. The burden shifts rather than decreases.
Defining which providers qualify as 'safety net' may create disputes. Enforcement could be complex and expensive. Administrative burdens might offset savings.
Drug supply chains could be disrupted if manufacturers limit availability to protected providers. Drug shortages in other markets are possible. Market competition dynamics may shift unexpectedly.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
No lobbying disclosures matched this bill.